Endo, Novartis begin agreement

Share this article:

Endo Pharmaceuticals has entered into a licensing agreement with Novartis to obtain the exclusive US marketing rights for Voltaren Gel (diclofenac sodium topical gel) 1%. Endo said it expects to commercialize Voltaren Gel using one of its two specialty sales forces, consisting of 160 reps, prior to executing a full physician launch in late May with an additional 275 contract sales reps targeting primary care physicians who prescribe both NSAIDs and Cox-2s.

Voltaren Gel received FDA approval in October 2007. Endo estimates US peak annual sales for Voltaren Gel as an osteoarthritis pain treatment in the range of $250-300 million. 
Share this article:

Email Newsletters

More in Features

Read the complete April 2014 Digital Edition

Read the complete April 2014 Digital Edition

Click the above link to access the complete Digital Edition of the April 2014 issue of MM&M, with all text, charts and pictures.

Antidote: Are e-cigarettes safe?

Antidote: Are e-cigarettes safe?

The pros and cons of e-cigarettes

Combating concept churn

Combating concept churn

There's no cure. But the good news is that prophylaxis is possible.